Spots Global Cancer Trial Database for A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
Official Title: A Phase 1 Dose-Escalation Study to Evaluate the Safety and Tolerability of HGS1029 (AEG40826-2HCl) in Patients With Advanced Solid Tumors
Study ID: NCT00708006
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Stanford University Dept. of Medicine-Oncology, Stanford, California, United States
University of Colorado Health Sciences Center, Aurora, Colorado, United States
The Sarah Cannon Research Institute, Nashville, Tennessee, United States
Contact Details
Name: Gilles Gallant, B. Pharm.,Ph.D.
Affiliation: Human Genome Sciences Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
